Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT +3.03%40 Days Sales Outstanding is 140.04 as of Jun. 2026, which is 13% below its 10-year median of 160.99. GuruFocus rates ADCT with a GF Score™ of 40/100 and a GF Value™ of $2.05 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, ADC Therapeutics ranks worse than 83.95% on this metric.
ADC Therapeutics (NYSE:ADCT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ADC Therapeutics Days Sales Outstanding Related Terms
ADC Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCT vs BGM, CPIX, LFCR: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Days Sales Outstanding falls into.
ADC Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 140.04 mean?
ADC Therapeutics (ADCT) has a Days Sales Outstanding of 140.04 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ADC Therapeutics and its competitors. This is 13% below median its historical median of 160.99. Over the past decade, ADC Therapeutics' Days Sales Outstanding has ranged from 29.95 to 708.04. According to the industry distribution chart, ADC Therapeutics ranks #795 out of 947 companies in the Drug Manufacturers industry, placing it in the top 83.9%.
Is ADC Therapeutics' Days Sales Outstanding too high?
ADC Therapeutics' current Days Sales Outstanding of 140.04 is 13% below median its 10-year median of 160.99. Over the past 10 years, this metric has ranged from a low of 29.95 to a high of 708.04. The Drug Manufacturers industry median Days Sales Outstanding is 71.85. ADC Therapeutics' value of 140.04 is 94.9% above this industry median. Based on the distribution chart, ADC Therapeutics ranks #795 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Days Sales Outstanding compare to BGM and CPIX?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #795 out of 947 companies for Days Sales Outstanding. This places ADC Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 71.85. ADC Therapeutics' value of 140.04 is 94.9% above this benchmark. Historically, ADC Therapeutics' own Days Sales Outstanding has ranged from 29.95 to 708.04 over the past decade. While the company's 10-year median is 160.99 vs. the industry median of 71.85, ADC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.85, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Days Sales Outstanding of 140.04 is 94.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Days Sales Outstanding is 140.04, which is 13% below median its own 10-year median of 160.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.05, compared to a current price of $1.36 — trading 33.7% below its estimated fair value. The current Days Sales Outstanding is 140.04, which is 13% below median its 10-year median of 160.99 and 94.9% above the Drug Manufacturers industry median of 71.85. ADC Therapeutics' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Days Sales Outstanding is 140.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.36 is trading 33.7% below its estimated GF Value™ of $2.05.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Days Sales Outstanding: 140.04 (13% below median its 10-year median of 160.99)
GF Value™: $2.05 vs. price of $1.36 (33.7% below fair value)
Industry Position: 94.9% above the Drug Manufacturers median (#795 of 947)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
40GF Score
Get the complete analysis for ADCT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
